-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MwVnpCQQcE1Cqc+uGZ6pH3Z1OZDzNScfcoosoSH/w2ymoRptijcW0Cv2ciccI/Ze ejlA0NuGTNdUWeyFOFMuAQ== 0000950005-02-000743.txt : 20020712 0000950005-02-000743.hdr.sgml : 20020711 20020711155820 ACCESSION NUMBER: 0000950005-02-000743 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020708 ITEM INFORMATION: Other events FILED AS OF DATE: 20020711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTIME INC CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 02701120 BUSINESS ADDRESS: STREET 1: 935 PARDEE ST CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 5108459535 MAIL ADDRESS: STREET 1: 935 PARDEE STREET CITY: BERKELEY STATE: CA ZIP: 94710 8-K 1 p15748_8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 8, 2002. BioTime, Inc. (Exact name of registrant as specified in its charter) 1-12830 (Commission File Number) California 94-3127919 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 935 Pardee Street Berkeley, California 94710 (Address of principal executive offices) (510) 845-9535 (Registrant's telephone number, including area code) Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements. Item 5. Other Events. The Health Products and Food Branch, Health Canada, has approved Hextend(R) for sale in Canada. Hextend is BioTime's proprietary hetastarch-based plasma volume expander with lactate, multiple electrolytes, and physiological amounts of glucose. Hextend will be marketed in Canada by Abbott Laboratories, Limited, Canada, an affiliate of Abbott International. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOTIME, INC. Date: July 9, 2002 By /s/ Paul Segall ---------------------------------------- Paul E. Segall Chairman and Chief Executive Officer 2 -----END PRIVACY-ENHANCED MESSAGE-----